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High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and 
overall survival has not changed significantly for several decades. In this Opinion article, we 
outline a set of research priorities that we believe will reduce incidence and improve outcomes for 
women with this disease. This ‘roadmap’ for HGSOC was determined after extensive discussions 
at an Ovarian Cancer Action meeting in January 2015.
A recognition of the cellular and molecular diversity of ovarian cancer, and the consequent 
need for a more refined approach to research and clinical trials, were the key points of a 
Nature Reviews Cancer Perspectives article arising from a Helene Harris Memorial Trust 
(HHMT) Ovarian Cancer Action (OCA) (BOX 1) meeting in 2011 (REF. 1). In contrast to 
that article, which considered ovarian cancer broadly, here we outline our consensus view on 
research priorities for a single subtype of ovarian cancer: high-grade serous ovarian cancer 
(HGSOC). HGSOC is of particular interest, as it accounts for most deaths from ovarian 
cancer, has shown little improvement in overall survival for decades, and shares substantial 
molecular similarity with basal-like breast cancer2. In addition, our understanding of the 
molecular aetiology and clinical pathology of HGSOC has greatly increased since 2011, 
making it important to review priorities in the light of recent research.
Although this disease is termed an ovarian cancer, pathological35, epidemiological6, 
molecular genetic7,8 and mouse model studies9 suggest that secretory epithelial cells of the 
distal fallopian tube (FTSECs) are the likely progenitors of a substantial proportion of 
HGSOCs (FIGS 1,2). However, even with improved methods for pathological assessment of 
fallopian tubes, some HGSOCs seem to arise without fallopian tube involvement. This is 
consistent with experimental mouse models of HGSOC: some models show a direct 
evolution from precursor cells in the fallopian tube9 and others seem to primarily involve 
precursor cells in the ovary10. It is unclear whether tumours arising without apparent 
fallopian tube involvement are associated with earlier seeding of the ovaries with FTSECs 
through a process known as endo salpingosis or whether they are truly ovary-derived 
diseases9,11. Missense or nonsense mutation mutations in TP53 are currently the earliest 
known molecular events in HGSOC and a near invariant feature of serous tubal 
intraepithelial carcinoma (STIC)12 and HGSOC13,14 (FIG. 1).
With the exception of TP53, BRCA1 and BRCA2, point mutations in oncogenes or tumour 
suppressor genes are relatively uncommon in HGSOC14. Instead, HGSOCs are characterized 
by genomic structural variation, with frequent DNA gains and losses, making this cancer an 
extreme example of a chromosomally unstable (C-class) malignancy15 (FIG. 1). Structural 
change is an important mechanism for inactivation of tumour suppressors in HGSOC, 
through heterozygous and homozygous loss16 and gene breakage17. Approximately 50% of 
HGSOCs are defective in the homologous recombination (HR) DNA repair pathway14,18,19. 
HR defects arise mainly from germline, somatic and epigenetic mutations in BRCA1 and 
BRCA2 (REF 20) and, to a lesser extent, from mutations in other components of the HR 
pathway21 (FIG. 1). HR deficiency is a key determinant of platinum sensitivity in HGSOC 
and provides a rational basis for the use of poly(ADP-ribose) polymerase (PARP) inhibitors, 
which further inactivate DNA repair in already compromised HR-defective tumours22–24.
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The molecular characteristics of the other half of all HGSOC — those that have no apparent 
defects in HR — are relatively poorly defined. Approximately 30% of this subclass have 
amplification of CCNE1 (which encodes the G1/S-specific cyclin E1)14, and this is likely an 
early event in the development of HGSOC25. Moreover, HGSOC cell lines in which CCNE1 
is amplified undergo cell cycle arrest or apoptosis following the loss of cyclin E1 or its 
protein partner, cyclin-dependent kinase 2 (CDK2)26, suggesting a novel therapeutic 
approach in patients.
Four molecular subtypes (C1/mesenchy-mal, C2/immune, C4/differentiated and C5/ 
prolifera tive) have been identified in HGSOC and vali dated by gene expression 
profiling14,27,28; these are associated with differential clinical outcomes and 
microenvironmental features such as immune and stromal cell activation. However, these 
molecular subtypes have not yet been integrated into the clinical setting. Recent studies have 
begun to unravel the determinants of metastatic spread of HGSOCs, including their tropism 
for adipocyte-rich omentum29 and a propensity for omental localization. Haematogenous 
peritoneal dissemination has been observed in a parabiosis preclinical mouse model, 
suggesting that spread of HGSOC throughout the abdomen may occur both passively and 
via the vasculature30.
MicroRNA (miRNA) dysregulation has been partially mapped in HGSOC, including the 
identification of mi RNAs that regulate genes associated with the C1/mesenchymal 
subtype31–33. A subset of HGSOCs have shown intratumoural infiltration with activated 
lymphocytes, in particular CD8+ T cells, and are generally associated with better overall 
survival. Patients with the C2/ immune subtype of HGSOC may benefit from use of immune 
checkpoint inhibitor therapy34.
In the light of this new information, at the January 2015 OCA meeting we considered areas 
of research and clinical practice that we believe will make the most impact on unravelling 
the molecular biology of HGSOC and developing more effective treatments. This Opinion 
article outlines seven key areas that we believe offer the most promise in tackling this 
disease (BOX 2). Supplementary information S1 (box) has a summary of this Opinion article 
for non-specialist clinicians and the interested public.
Improve current experimental models
Cell lines, patient-derived xenograft (PDX) models and genetically engineered mouse 
(GEM) models of HGSOC are needed to address different experimental contexts.
Cell lines
Recent studies35,37 have highlighted the inadequacy of many commonly used ovarian cancer 
cell lines as models of HGSOC. We strongly recommend that research on HGSOC should 
use extensively characterized cell lines that accurately reflect the disease, and that their 
detailed characteristics should be provided in all manuscripts. Development of improved 
approaches to generate primary cultures from patients38,39 will assist in producing more 
effective and accessible models. Collaborative efforts should be directed at creating large 
sets of genomically and functionally characterized HGSOC cell lines, with clinical 
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annotation and representation of key mutational drivers, such as loss of BRCA1, BRCA2, 
RB1 or NF1 (neurofibromin 1), amplification of AKT, PIK3CA (PI3K catalytic subunit-α), 
MYC or CCNE1, and those with a range of nonsense and missense TP53 mutations. Culture 
conditions that more closely resemble the tumour microenvironment — including three-
dimensional (3D) matrices and co-cultures of malignant cells with fibroblasts and 
mesothelial cells40,41 — may also improve success in obtaining continuous, biologically 
relevant cell lines with stable biologic features. Immortalized FTSECs seem to be the most 
appropriate normal control for HGSOC42–44, but further molecular and functional 
characterization is required of the handful of currently available FTSEC lines42. 
Consideration should be given to generating additional ovarian surface epithelial lines to 
better understand the role of these cells in HGSOC development.
Mouse models
Considerable progress has been made in recent years in the development of mouse models of 
ovarian cancer. There are now several GEM models that direct transformation specifically to 
FTSECs and that histologically and molecularly9 resemble human HGSOC, including 
models with mutant Trp53 and conditional inactivation of Pten and Brca1 or Brca2 (REFS 
8
,
9) (FIG. 2). Importantly, these models recapitulate the development of the STIC precursor 
lesion9,45. Additional GEM models of other driver events, such as CCNE1 or MYCN 
amplification, would facilitate studies of other molecular subsets of HGSOC. Novel genome 
editing technologies may simplify the generation and utility of these new GEM models46. 
Their value will be further enhanced by derivation of transplantable tumour cell lines from 
these mice with a fully syngeneic background, to allow well-controlled in vitro and in vivo 
experiments.
PDXs grown in immunocompromised mice at least partially recapitulate the clinical 
responses and resistance mechanisms that are observed in patients47–50. However, we 
believe that it is premature to use PDX models derived from specific patients, also known as 
avatars
51
, as a commercial assay to guide drug selection in individual patients. There may be 
value in exploring humanized mouse models, made by the engraftment of human 
haematopoietic bone marrow stem cells52, to overcome the limitations of immune-deficient 
PDX models. A comprehensive range of HGSOC models is needed to reflect the clonal 
diversity and the range of acquired resistance mechanisms that have recently been 
identified17.
Understand determinants of drug response
Compared with other solid cancers, HGSOCs are unusually sensitive to platinum-based 
chemotherapy and other DNA-damaging agents, and are frequently amenable to retreatment, 
even with the same or similar agents to those that were used in the first-line setting. 
However, treatment resistance eventually emerges in 80–90% of those patients who are 
initially diagnosed with widespread disease. Genomic studies have shown that substantial 
clonal diversity exists in patients who have not yet received chemotherapy53–56, providing a 
mechanism for the development of resistance. Novel bioinformatic tools that accurately 
Bowtell et al. Page 6
Nat Rev Cancer. Author manuscript; available in PMC 2016 June 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
identify and quantify tumour subclones are needed to investigate the evolution of HGSOC 
genomes under the selective pressure of therapy57.
In contrast to the existing extensive genomic datasets obtained with primary HGSOC 
samples, only a handful of recurrent HGSOC samples collected at disease recurrence have 
been analysed in depth. Consortia such as OCTIPS (Ovarian Cancer Therapy – Innovative 
Models Prolong Survival) and the British Translational Research Ovarian Cancer 
Collaborative (BritROC) are focused on obtaining and analysing large intra-patient paired 
tumour sample sets. Even among the limited number of recurrent samples analysed so far, 
there is an apparent diversity of acquired resistance mechanisms, including the activation of 
AKT signalling58, the reversion of germline mutations in BRCA1 and BRCA2 through 
intragenic second-site mutations that restore the open reading frame of defective 
transcripts17,59,60, the loss of BRCA1 methylation17, a shift to a higher stromal content 
(known as a desmoplastic phenotype) and overexpression of the drug transporter ABCB1 
through promoter hijacking17. Targeting of AKT has recently shown promising clinical 
activity in combination with carboplatin and paclitaxel in a Phase Ib/II study of platinum-
resistant ovarian cancer61. Expression of markers of autophagy is increased in dormant, 
drug-resistant tumour nodules found on the peritoneal surface in recurrent disease compared 
with primary disease62, suggesting that targeting autophagic processes may be important in 
overcoming dormancy in HGSOC.
Because only a small number of recurrent tumour samples have been analysed and 
characterized so far, it is likely that we have underestimated the number of acquired 
resistance mechanisms. For example, it is unclear whether disease relapse results from the 
expansion of self-renewing cellular populations, a change in the extracellular matrix, the 
emergence of drug-resistant clones or a combination of these events, between and within 
individual patients. We therefore believe that there should be a major effort to characterize 
recurrent and end-stage samples. Given the importance of understanding resistance, biopsies 
should be collected at recurrence to generate collections of highly valuable paired pre- and 
post-treatment samples. Research autopsy studies17 allow comprehensive sampling to map 
the diversity of resistance and the collection of large amounts of material for genomic, 
proteomic, PDX, and immunological and biochemical studies of end-stage disease. Using 
laparoscopy (minimally invasive surgery for direct visualization of tumours) for tumour 
mapping, sample collection and prospective monitoring of response to chemotherapy, in 
particular in the neoadjuvant setting, in eligible patients also offers promise for 
understanding tumour evolution under primary chemotherapy. Moreover, recent advances in 
methods of isolating cell-free tumour DNA from patients’ plasma samples (liquid biopsies) 
provide additional, non-invasive means to measure changes in tumours and to understand 
how cancers evolve in response to treatment63.
Much of the research on HGSOC focuses on the reasons why some patients have a limited 
response to chemotherapy. However, it is also important to characterize the molecular 
determinants of exceptional responders64: those rare patients with extensive post-operative 
residual disease who have a dramatic and prolonged response to chemotherapy. Exceptional 
responders may provide insights into the contribution of immunological, stromal or other 
factors that are important for long-term survival. Comparison of patients with long versus 
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short overall survival may help us to understand how clonal diversity before treatment, 
genomic instability and the type of host antitumour response influence the emergence of 
drug resistance. Indeed, a better understanding of host responses to primary and relapsed 
HGSOC is likely to be central to improving outcomes.
Understand the tumour microenvironment
HGSOC was one of the first human cancers in which an association was found between an 
increased density of intraepithelial tumour-infiltrating lymphocytes (TILs) and longer patient 
survival34. Tumour-reactive TILs65 found in HGSOC (FIG. 3) recognize shared tumour 
antigens such as ERBB2 (also known as HER2), cancer/testis antigen 1 (CTAG1B), 
mesothelin (MSLN) and telomerase reverse transcriptase (TERT)66, as well as neoantigens, 
all processed and presented by major histocompatibility complex (MHC) class I 
molecules67. However, TILs are often suppressed or even functionally exhausted in solid 
cancers owing to a variety of factors, including: chronic antigen exposure; immune 
suppressive cytokines (such as interleukin-10 and transforming growth factor-β (TGFβ)); the 
leukocyte surface antigen CD47 (REF. 68); metabolite deprivation (including tryptophan 
depletion by overexpression of indoleamine 2,3-deoxygenase 1 (REF. 69)); immune 
checkpoint molecules such as programmed cell death protein 1 ligand 1 (PDL1)70,71; and 
the presence of immunosuppressive regulatory T cells and myeloid cells72 (FIG. 3). Further 
characterization of the role of immunosuppressive factors in HGSOC is required.
Immune checkpoint inhibition has yielded impressive clinical responses in melanoma and 
non-small cell lung cancer73, perhaps owing to the exceptionally high mutational loads in 
these malignancies74,75. By contrast, HGSOC has an intermediate mutational load14,67,76, 
and consequently the abundance of neoantigens derived from point mutations is expected to 
be lower in this disease76. TILs are particularly prominent in BRCA1 -mutant tumours77–80 
for reasons that are unclear. A prominent TIL response is less commonly associated with 
BRCA2-mutant tumours even though they have more point mutations than tumours with a 
BRCA1 mutation81, indicating that factors other than point mutation load can influence TIL 
response. The immunogenicity of HGSOC may involve other classes of tumour antigens, 
such as amplified or aberrant gene products arising from gene fusions. The B cell repertoire 
is altered in BRCA1 -mutant carriers82, suggesting another means by which this germline 
mutation might affect the tumour microenvironment of HGSOC. An improved 
understanding of the determinants of TIL density in HGSOC may assist in the development 
of immune checkpoint therapies in this disease.
Although numerous studies have confirmed the prognostic significance of intraepithelial 
TILs in HGSOC27,34, there is currently no consensus on how best to classify immune 
infiltrates in HGSOC biopsy samples, either for up-front stratification of patients in clinical 
trials or for post-trial evaluation. With considerable attention now focused on understanding 
the drivers of the immune repertoire in HGSOC, there is a need to collaboratively develop 
standard criteria, similar to the ‘immunoscore’ used to characterize colorectal cancer 
samples83. The development of a well-defined HGSOC immunoscore may require 
multiplexed immunohistochemistry to capture essential prognostic features, such as immune 
cell type, functional orientation, location in the tumour and density. Codifying essential 
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elements of an immunoscore would facilitate the comparison of findings from various 
clinical trials of immune modulators. Patients whose tumours have a high immunoscore may 
be suitable for immune checkpoint blockade or adoptive T cell therapies84, whereas those 
with an intermediate immunoscore may benefit from agents that stimulate CD8+ T cell 
trafficking and infiltration. Tumours with a low immunoscore could potentially be treated 
with vaccines that prime new T cell responses or with engineered T cells, such as chimeric 
antigen receptor (CAR) T cells that circumvent deficiencies in the tumour-specific T cell 
repertoire. Studies in lung85, breast, colon and ovarian86 cancer cell lines and patient 
samples show that epigenetic therapies, including DNA demethylating agents87–89 and some 
chemotherapeutic agents, can stimulate immune signalling from epithelial cells and may 
therefore benefit patients with low or absent TILs.
Although TILs are a prominent feature of the tumour microenvironment, their functional 
phenotype and prognostic effects are strongly influenced by other cell types. The presence of 
CD20+ B cells in the tumour epithelium90 and of stromal plasma cells correlate with a better 
prognosis, whereas regulatory T cells, macrophages and immature myeloid cells may 
promote tumour formation91 (FIG. 3). These results are reminiscent of data from colorectal 
cancer illustrating a common immune phenotype between cancer types92,93.
Beyond immune cells, the tumour microenvironment of HGSOC has other important 
elements that may influence treatment response, including fibroblasts, endothelial cells and 
the extracellular matrix. Recent studies have revealed dynamic interactions between HGSOC 
and the single cell layer of mesothelial cells that line the peritoneum and pleural 
cavity41,94,95 as well as with cancer-associated fibroblasts96 and adipocytes29. These 
interactions influence tumour spread, metabolism, epithelial- mesenchymal transition and 
extracellular matrix deposition96,97, which may in turn affect drug penetration and response 
to chemotherapy98,99. To devise better targeting strategies, it is important to understand 
whether stromal responses promote or restrain HGSOC100,101. Although several Phase III 
trials have documented the long-term clinical effectiveness of intraperitoneal chemotherapy, 
the mechanism of action has not been resolved. It is assumed the effectiveness of 
intraperitoneal chemotherapy is associated with higher drug concentrations in the tumour; 
however, it is possible that intraperitoneal chemotherapy also alters the interaction of 
HGSOC with mesothelial cells, which can promote the establishment of metastases in 
HGSOC41,94.
Given the profound sensitivity of HGSOC to platinum-based chemotherapy, additional 
longitudinal studies are required to elucidate the impact of standard treatments on the 
various cell populations in the tumour microenvironment. Moreover, the complexity of the 
HGSOC tumour microenvironment means that combination therapies targeting different 
elements are more likely to be successful than single agent approaches. For example, a 
current clinical trial combines a Toll-like receptor 8 (TLR8) agonist to activate antigen-
presenting cells, liposomal doxorubicin to stimulate immunogenic tumour cell death, and 
PDL1 blockade to activate T cells (ClinicalTrials.gov identifier NCT02431559).
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Stratify patients in trials
The realization that the different types of epithelial ovarian cancer are distinct malignancies 
has driven the development of histotype-specific clinical trials in recent years. Similarly, an 
improved understanding of the biology of HGSOC is providing impetus for stratified trials 
targeting distinct molecular subsets of HGSOC.
HR-defective HGSOC
The pivotal observation of synthetic lethality using PARP inhibitors in BRCA1- and 
BRCA2-mutant ovarian cancer cell lines102 led to the development of one of the most 
important new classes of targeted agents in HGSOC23. Although PARP inhibitors have been 
most active in patients with either germline or somatic mutations in BRCA1 or BRCA2 
(REF. 103), significant responses have also been observed in a proportion of non-BRCA-
mutant tumours; these tumours might respond because they carry mutations in other genes 
involved in the HR pathway. The reliable prediction of patient response is an important 
priority for the development of PARP inhibitors in HGSOC. Although DNA sequencing of 
all genes involved in the HR pathway is technically feasible, tests that integrate the effects of 
HR loss, such as functional cellular assays18 or measuring the genome-wide consequences 
of defective HR104 (socalled genomic scarring), may provide a more effective way of 
identifying the patients who are most likely to respond to PARP inhibitors105. Reversion of 
germline BRCA1 or BRCA2 alleles may contribute to clinical drug resistance17,59,60,106. 
Emphasis should be placed on the identification of additional mechanisms of resistance 
through the analysis of samples collected during disease progression. As has been observed 
in patients treated conventionally with platinum agents, there are some exceptional 
responders to PARP inhibitors, and it will be interesting to discover whether the 
determinants of long-term response to platinum agents and PARP inhibitors are shared.
Anti-angiogenesis
HGSOCs express high levels of pro-angiogenic proteins that contribute the development of 
ascites seen in many patients. Therefore, considerable effort has gone into exploring the 
activity of anti-angiogenic agents in HGSOC, particularly those attenuating the activity of 
vascular endothelial growth factors (VEGFA and VEGFB). Although the VEGF-specific 
monoclonal antibody bevacizumab in combination with chemotherapy results in improved 
progression- free survival in patients in a first-line setting107,108 and in platinum-resistant 
recurrent ovarian cancer109, its impact has been modest, and there is no evidence of an 
increase in overall survival110,111. Resistance to bevacizumab emerges in most patients with 
HGSOC who initially respond, but how this occurs remains unclear.
It seems that effective targeting of angiogenesis in this disease is unlikely to be established 
easily. We therefore recommend that greater effort should be placed on identifying predictive 
biomarkers, understanding the mechanisms of acquired resistance to angiogenesis inhibitors 
through the collection of tissue and blood samples from patients enrolled in clinical trials, 
and the rational development of combination strategies. One recent attempt to identify 
biomarkers of response to bevacizumab involved transcriptional profiling of samples112 
collected during the ICON7 clinical trial. Surprisingly, patients whose tumour samples had 
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high expression of immune response genes and who received bevacizumab had shorter a 
progression-free and overall survival than patients who did not receive bevacizumab 
maintenance therapy112. If validated, this gene expression profile may provide a useful 
approach to patient selection and improve our understanding of how different subtypes of 
HGSOC respond to anti-angiogenic agents. Other molecular agents targeting angiogenesis 
are in preclinical and clinical development113,114. Recent results with the VEGF receptor 
inhibitor cedarinib and the PARP inhibitor olaparib115 suggest that combinations of anti-
angiogenic agents with other targeted treatments may be beneficial.
Umbrella trials
The identification of actionable mutations in solid cancers such as lung and breast cancer has 
led to socalled umbrella trials, in which patients are stratified for treatment according to the 
molecular properties of their tumours and not the site of cancer origin116. Although the 
limited number of actionable mutations in HGSOC14 makes the design of umbrella trials 
challenging, tumours with HR deficiency, amplified genes such as CCNE1 or AKT1 and 
AKT2 (also known as PKB and PKBB) or loss of PTEN are all suitable for this kind of 
stratification. The search for novel therapeutic targets should continue by using techniques 
such as synthetic lethal small hairpin RNA117,118 and CRISPR (clustered regularly 
interspaced short palindromic repeats) cell line screens, the high-throughput evaluation of 
drug combinations119, and making use of more appropriate HGSOC cell lines and 
sophisticated culture conditions. Highly multiplexed imaging120 of the cell surface of 
HGSOC may provide further novel molecular targets and insights to HGSOC biology.
Although receptor tyrosine kinases (RTKs) are overexpressed in HGSOC, response to 
single-agent RTK inhibitors has been disappointing121. Recent findings suggest the 
expression of several RTKs may be deregulated through a novel mechanism associated with 
methylation-induced loss of expression of OPCML (opioid binding protein/cell adhesion 
molecule-like), which is a member of the IgLON family of cell surface proteins that 
modulate receptor recycling122. Understanding the pathway associated with OPCML 
signalling may provide new strategies to revisit the use of RTK inhibitors in HGSOC.
The simple genetic background of other, rarer histological subtypes may also offer the 
opportunity to study the consequences of some of the less frequent epigenetic and/ or 
mutational alterations found in HGSOC. For example, although missense or deletion 
mutations in the SWI/SNF ATPase subunit SMARCA4 (encoding the transcription activator 
BRG1) are reported in only 2% of HGSOC cases123,124, this gene is ubiquitously mutated in 
hypercalcaemic-type small cell carcinoma of the ovary125. The self-renewing compartment 
of HGSOC is only partially defined126 and may provide insights into new molecular targets 
for HGSOC. Specifically, molecular characterization of HGSOC stem cells is an important 
priority for developing maintenance therapeutic approaches that target residual cells 
following debulking surgery127–129.
There is a need for clinical trial protocols that allow rapid evaluation of new compounds and 
combinations of treatments. In breast cancer, window-of-opportunity studies130, in which 
new agents are evaluated for a short period of time before surgical resection of the primary 
cancer, are common. A similar approach could be used in HGSOC, whereby biopsies are 
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carried out at initial diagnosis, followed by several cycles of treatment with a new agent or 
combination of agents before cytoreductive surgery. This approach would use pre- and post-
treatment tumour material to evaluate pathological response as a surrogate endpoint for 
survival, and such samples could be used for biomarker studies. First relapse provides 
another setting for testing new agents in HGSOC patients. Although evaluation of new 
agents at relapse may delay the start of standard treatments, this may be acceptable, as the 
timing of initiating standard treatment during disease recurrence does not seem to affect 
outcome
131
.
Implement strategies on prevention
Understanding the biology of HGSOC and developing new therapeutic approaches is 
challenging, complex and time consuming. However, there are already ways to reduce risk 
and improve clinical outcomes. Oral contraceptives provide lasting risk reduction in both the 
general female population and in women who carry germline BRCA1 or BRCA2 
mutations132, with duration of oral contraceptive use being proportional to the decrease in 
risk. It is important that women, especially those at increased genetic risk of ovarian cancer, 
are aware of this benefit. Further research is needed to understand the basis of protection 
provided by oral contraceptive usage, particularly at a time when intrauterine devices are 
increasingly favoured for contraception in younger women. Results from two 
epidemiological studies suggest that chronic use of aspirin to alleviate non-cancer conditions 
is associated with the unexpected benefit of reducing the incidence of epithelial ovarian 
cancer
133
,
134
 and that the diabetes drug metformin is associated with improved survival in 
women with ovarian cancer135,136. If these findings are confirmed, repurposing well-
established drugs with low toxicity profiles may be valuable in reducing disease burden in 
high-risk individuals. Conversely, a meta-analysis of 52 epidemiological studies indicates 
that use of hormonal therapy for menopause moderately increases the risk of ovarian cancer, 
particularly for serous tumours, most of which are HGSOCs137. Obesity also increases the 
risk of serous ovarian cancer138. There is an urgent need to understand why there are 
substantial racial and socioeconomic disparities in the treatment and outcome of women 
with HGSOC and take steps to close the gap139.
Germline mutations in BRCA1 and BRCA2 are present in 15–18% of patients with 
HGSOC, and approximately half of all carriers lack a significant family his-tory20,140–143. 
We believe that germline testing should be offered to all women with HGSOC, irrespective 
of age or family history, with testing done at diagnosis as it provides information about their 
likely response to therapy20,103,144. In addition, there is a case for population testing for 
founder mutations in BRCA1 and BRCA2 in high-risk populations such as Ashkenazi 
Jewish women, in whom BRCA1 and BRCA2 mutations are prevalent. A recent randomized 
controlled trial involving Ashkenazi Jewish women aged 30 years and older showed that 
population-based testing could be achieved at an acceptable cost and did not adversely affect 
short-term psychological and quality-of-life outcomes145,146. There is also a need to develop 
more-effective approaches to ‘cascade genetic testing’ (REF. 147): predictive genetic testing 
offered to relatives of index mutation carriers to maximize the opportunities for breast and 
ovarian cancer risk reduction in female family members and prostate cancer in males.
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Less commonly than BRCA1 or BRCA2, patients with HGSOC may have germline 
mutations in other genes involved in HR, including BRIP1 (BRCA1 -interacting protein 1), 
BARD1 (BRCA1 -assoociated RING domain 1), RAD51B and RAD51C148–151. In addition, 
a series of low risk alleles have been identified through genome-wide association studies152, 
but they are currently not clinically actionable. Large cohort studies of population-based 
cases and controls are needed to understand the penetrance of these mutations — including 
their interaction with high- and moderate-risk alleles, and the effect of carrying multiple 
low-risk alleles — and provide useful advice to carriers about their risk of developing 
ovarian cancer152. Clinical panel testing for both high- and moderate-penetrance genes is 
widely available. Care is needed in counselling unaffected women with moderate-penetrance 
mutations in terms of ovarian cancer risk-reducing options. In particular, until a better 
estimate of risk is obtained, we believe that it is premature to offer panel genetic testing 
beyond BRCA1 and BRCA2 as part of routine clinical care for HGSOC. As increasing 
numbers of women at elevated risk of HGSOC are identified through more comprehensive 
genetic screening, it will be important to understand the psychosocial153 and medical needs 
of women who are at risk but have not yet developed cancer154.
The improved understanding of the role of the fallopian tube in the genesis of HGSOC has 
important implications for clinical management. For example, as most hereditary HGSOC 
are thought to derive from the fallopian tube, removal of only the tubes (salpingectomy) is 
being considered in young BRCA1- or BRCA2-mutant carriers to avoid the effects of early 
menopause that are triggered by removal of the ovaries (oophorectomy)155. However, 
oophorectomy, and the consequent reduction in oestrogen levels, has an added benefit of 
breast cancer risk reduction in young mutation carriers, and this benefit is absent with 
salpingectomy only. Hence, there is a need to understand the overall benefits versus side 
effects of these different approaches in young patients carrying BRCA1 or BRCA2 
mutations.
Although most HGSOCs may be fallopian tube-derived, there is a subset of HGSOCs with 
no apparent precursor lesion in the fallopian tube, and so to develop additional prevention 
strategies we need to understand how these arise. For instance, further investigation is 
required of the impact of initial salpingectomy followed by oophorectomy once natural 
menopause has occurred. Researchers from the British Columbia Cancer Agency are 
currently investigating the value of removing fallopian tubes in every woman undergoing a 
hysterectomy, as a practical, population-based, opportunistic approach to reducing ovarian 
cancer incidence156.
The identification of increasing numbers of ‘at-risk’ mutation carriers through wider genetic 
screening157 highlights the need for continued efforts to develop an effective screening 
strategy. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial using 
the blood tumour biomarker CA125 and ultrasound showed no reduction in mortality158. 
Recent results from the United Kingdom Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) based on serial CA125 profile seem encouraging159, although evidence of a 
mortality impact is awaited. Meanwhile, continued efforts are needed to improve early 
detection strategies, given the prognostic significance of disease burden at presentation160. 
Research efforts should be based on the understanding of the natural history of HGSOC, 
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with a focus on detection of low-volume disease rather than low-stage disease alone161. 
Future strategies need to incorporate time series algorithms to interpret markers159,162. Other 
approaches include the development of cancer-specific markers such as targeted deep 
sequencing of DNA for TP53 and other gene mutations in plasma163 or cervical 
secretions164, and improved165,166 imaging. Early detection is always going to be a 
challenge in HGSOC because the disease is often asymptomatic before peritoneal spread.
Define the value of cytoreduction
Pre-operative tumour load and post-operative residual disease are the most important 
prognosticators of survival in advanced-stage HGSOC160,167–169. However, we still do not 
fully understand which patients are most likely to benefit from primary cytoreductive 
surgery (or debulking) or how extensive the surgical effort should be170. In addition, the 
timing of surgery remains contentious. The value of neoadjuvant chemotherapy and interval 
debulking (three cycles of chemotherapy followed by surgery and a further three cycles of 
chemotherapy) has been established in terms of equivalent overall survival with lower 
morbidity compared with primary debulking surgery169. However, this research was 
conducted in a setting of limited surgical resection, as evidenced by low rates of optimal 
cytoreduction and total macroscopic tumour clearance. New trials in specialized centres with 
experience in maximal surgical effort are needed to re-examine the value of neoadjuvant 
chemotherapy in advanced disease.
Surgical management of HGSOC should integrate molecular markers with current clinical 
and pathological factors into an algorithmic approach to surgery171. Surgical options include 
primary or interval debulking or, indeed, no surgery at all in patients with extensive disease 
and a reliance on chemotherapy alone. The development of biomarkers that reliably predict 
surgical resectability, or rapid relapse despite optimal surgery, is an important priority for the 
stratification of patients for these surgical options172. The ability to surgically clear all 
macroscopic tumour tissue (optimal debulking) is influenced by anatomical location and 
bulk of disease160, surgical skill, the fitness of the patient to undergo extensive surgery and 
the intrinsic biology of the epithelial and of other tumour microenvironment components, 
including TGFβ pathway activation96,173. For example C1/mesenchymal molecular subtype 
tumours have lower rates of optimal debulking and are characterized by a desmoplastic 
phenotype, which is associated with TGFβ activation27.
The wider use of an initial diagnostic laparoscopy to assess the extent of peritoneal and 
visceral involvement could assist in triaging patients to primary versus interval debulking 
surgery while obtaining highly valuable, high-quality research samples174. Expanded use of 
diagnostic laparoscopy may also allow improved prediction of surgical time and the 
expertise required to achieve optimum debulking surgery. However, no prospective 
randomized data exist so far to prove the accurate predictive and prognostic value of 
diagnostic laparoscopy in advanced ovarian cancer, so additional clinical testing is essential.
Although there is no prospective evidence for a survival benefit of secondary cytoreduction 
after completion of first-line treatment in platinum-sensitive tumours175, numerous 
retrospective studies have associated total macroscopic tumour clearance with a significantly 
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prolonged progression-free and overall survival, even at the relapsed setting of the 
disease176,177. Two large, multicentre, prospectively randomized surgical trials (the AGO–
OVAR OP.4/DESKTOP III and the GOG0213) are expected to define for the first time the 
value of secondary surgical cytoreduction at the time of first platinum-sensitive relapse. 
Cytoreductive surgery at relapse could also be combined with window-of-opportunity 
studies.
Move to an integrated view of HGSOC
Genomic analyses, particularly The Cancer Genome Atlas exome, methylome, and 
transcriptome study of more than 500 primary HGSOC samples, have provided a 
comprehensive picture of the mutational landscape of primary HGSOC. Although this is an 
invaluable reference dataset, it falls short of explaining how specific mutations interact to 
achieve the hallmarks of cancer178 in an individual patient. Currently, other than 
understanding that mutation in TP53 is both an early and invariant event, we know little of 
the temporal sequence of other molecular changes or the dynamics of chromosomal 
instability that drive the high degree of genomic aberration in HGSOC. Studies of the 
molecular changes in precursor lesions, and examination of allelic frequencies of copy 
number changes and driver mutations, may identify common early, so-called trunk 
mutations16. The centrality of TP53 mutation for HGSOC suggests that understanding its 
impact on FTSEC behaviour may provide important insights into initiating events in 
HGSOC. Indeed, a better understanding of the normal cellular biology of FTSECs as a 
whole, including growth factor requirements and determinants of self-renewal, is warranted 
to help interpret how specific mutations and copy number changes affect the behaviour of 
HGSOC.
PAX8 is a critical determinant of development of the fallopian tube179 and is 
expressed180,181 and required117 in almost all HGSOCs. Therefore, PAX8 may also hold 
clues regarding the molecular circuitry of HGSOC. The tropism of HGSOC for the omentum 
derives from its propensity to use fat as an energy source29, which has provided some of the 
first insights into the metabolic requirements of HGSOC and the determinants of metastatic 
spread. Metabolomic and proteomic studies, such as the National Cancer Institute Clinical 
Proteomic Tumor Analysis Consortium (CPTAC)182, are needed to help interpret current 
genomic data and provide insights into post- transcriptional, metabolic183, signalling and 
growth factor requirements of HGSOC. Studies that integrate genomic, epigenomic, 
proteomic, immune and other tumour microenvironment characteristics in a common set of 
primary and recurrent tumours would be especially informative.
Conclusion
The experimental approaches described here reflect some of the questions that limit the 
successful management of patients with HGSOC. Only by implementing a more 
comprehensive and collaborative research approach can we reduce incidence and deliver the 
long-awaited improvements in survival from a disease that kills an estimated 150,000 
women every year.
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Box 1 | The Helene Harris Memorial Trust meeting on which this article is 
based
Ovarian Cancer Action’s international research meeting (Helene Harris Memorial Trust 
(HHMT)), has been fostering communication between international ovarian cancer 
experts for more than 25 years. With a view to synchronize key ideas and maximize 
impact in the field, Ovarian Cancer Action brings together the world’s leading scientists 
and clinicians who are dedicated to improving the early detection of ovarian cancers and 
the treatment of patients with advanced-stage disease (see the Ovarian Cancer Action 
website for further information). In January 2015, experts met at the HHMT Ovarian 
Cancer Action 13th International Forum to debate the latest findings in basic, 
translational and clinical research in high-grade serous ovarian cancer (HGSOC). This 
article outlines the consensus of the meeting in terms of research priorities, strategies and 
recommendations for reducing incidence and improving outcomes for women with 
HGSOC. The listed authors have all contributed to this manuscript.
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Box 2 | Research priorities for reducing incidence and improving outcomes 
for women with HGSOC
Develop better experimental models
• Develop genomically characterized cell lines and improve methods for growing 
primary malignant cells and cancer-initiating cells
• Use three-dimensional cultures with other cells in the tumour microenvironment
• Develop patient-derived xenografts that recapitulate clinical responses and 
resistance
• Develop genetic mouse models that reflect the molecular biology and natural 
history of the human disease and syngeneic transplantable lines from these
Exploit immune responses and interaction with other tumour microenvironment 
cells
• Activate suboptimal antitumour immune responses
• Develop an immunoscore for prognostic and therapeutic use
• Study the impact of chemotherapy on the tumour microenvironment
• Understand stromal influences on response to drugs and tumour metabolism
Prioritize the understanding of clonal diversity, recurrent disease and exceptional 
responders
• Analyse recurrent and end-stage disease samples to map acquired resistance 
mechanisms
• Understand the impact of tumour-initiating cells, resistant clones and changes to 
the extracellular matrix on relapse
• Characterize clonal heterogeneity and genomic instability in acquired resistance
• Understand the mechanisms of exceptional responses to treatment
Transition to stratified trials of high-grade serous ovarian cancer HGSOC subsets
• Molecularly stratified clinical trials based on homologous recombination 
deficiency, cyclin E1 (CCNE1), AKT1 or AKT2 amplification, PTEN loss 
and/or molecular subtypes
• Target mechanisms of self-renewal and dormancy
• Evaluate new agents using laparoscopic diagnosis followed by neoadjuvant 
treatment, interval debulking surgery and measurement of pathological response
• Perform clinical trials of new agents in first relapse of both platinum-resistant 
and platinum-sensitive disease
Implement strategies that could make a rapid impact on prevention and clinical 
care
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• Highlight the preventive activity of oral contraceptives
• Repurpose drugs with low-toxicity profiles as preventive agents
• Research the value of salpingectomy versus oophorectomy or both
• Effective cascade genetic testing of relatives of affected women and population 
testing for founder mutations in high-risk groups
Better define the value of surgical cytoreduction
• Research the value of neoadjuvant surgery in advanced-stage disease
• Develop biomarkers to optimize time of surgery for each patient
• Use diagnostic laparoscopy more widely to assess a patient’s suitability for 
surgery
• Revisit ‘second-look’ surgery to combine with ‘window-of-opportunity’ trials
Move from ‘parts list’ to integrated view
• Study the molecular changes in precursor lesions
• Understand the biology of fallopian tube secretory cells and the role of PAX8
• Add metabolomics and proteomic information to genomic and transcriptomic 
profiles of HGSOC
• Integrate all -omics data on individual samples with immune and other tumour 
microenvironment components in primary and recurrent samples
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Figure 1. Clinical and molecular features of HGSOC at a glance
a | High-grade serous ovarian cancer (HGSOC) is thought to arise predominately from the 
secretory cells of the fallopian tube, from where there is no barrier to peritoneal spread. 
HGSOCs have a tropism for omental fat, which they use as an energy source. b | HGSOC is 
characterized by an initial favourable response to platinumbased therapy but then cycles of 
relapse and the development of acquired resistance to chemotherapy, as depicted by this plot 
of CA125 levels in a representative patient showing a typical clinical course. Triangles and 
diamonds indicate administration of different lines of chemotherapy. c | TP53 mutations are 
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a near-invariant feature of HGSOC but somatic point mutations in other driver genes occur 
at a low frequency. The data shown here were taken from 300 HGSOC tumours in The 
Cancer Genome Atlas database. d | The frequency of key driver mutations in HGSOC, 
including point mutations, amplifications or gene loss through structural variation (generated 
from data posted on the cBio Cancer Genomics Portal, Memorial Sloan-Kettering Cancer 
Center (MSKCC) and REF. 17). Approximately half of all HGSOCs show mutational and 
functional evidence of putative homologous recombination (HR) deficiency, including 
germline mutations in BRCA1 or BRCA2 in 15–17% of patients. Cyclin E1 (CCNE1) 
amplification represents an important subset of HR-intact tumours, and recent data increases 
the proportion of tumours with NF1 (neurofibromin 1) and RB1 loss. Somatic and germline 
mutations in components of HR are generally mutually exclusive, as are CCNE1, BRCA1 
and BRCA2 mutations; however, other mutations can co-occur such that individual tumours 
can have more than one of the driver events represented here. e | Graph showing cancer types 
dominated by either mutations (M class) or copy number changes (C class). HGSOC is one 
of the most chromosomally structurally variant malignancies. AML, acute myeloid 
leukaemia; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CRC, 
colorectal carcinoma; GBM, glioblastoma; HNSCC, head and neck squamous cell 
carcinoma; KIRC, kidney clear-cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung 
squamous cell carcinoma; UCEC, uterine carcinoma. Part e of the figure is from REF 15, 
Nature Publishing Group.
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Figure 2. Fallopian tube origins of HGSOC
Animal modelling of high-grade serous ovarian carcinoma (HGSOC) by targeting the 
fallopian tube and reflecting known mutations in human tumours. a | Different stages of 
HGSOC development in the human fallopian tube marked by p53 staining and cellular 
morphology. A substantial proportion of HGSOC arises from the fallopian tube, most likely 
PAX8-positive fallopian tubes secretory epithelial cells (FTSECs). p53 staining marks clonal 
expansion of cells (signatures) in the absence of morphological transformation of the 
fallopian tube epithelium. Piling up of cells and loss of epithelial architecture occurs in early 
lesions (tubal intraepithelial carcinoma (TIC)), finally leading to invasive cancer. b | 
Crossing strategy to generate a conditional, Cre-recombinase driven model of HGSOC in 
mice with Trp53 missense mutation, mutation in Brca1 or Brca2, and dysregulation of the 
PI3K–PTEN pathway. c | The histological appearance of mouse tumours parallels what is 
seen in human HGSOC. H and E, haematoxylin and eosin; rtTA, reverse tetracycline-
controlled transactivator; TetO-Cre, tetracycline-driven Cre recombinase. Part a of the figure 
is in part reproduced with permission from REF. 184, Elsevier. Figure parts b and c are 
adapted with permission from REF. 9, Elsevier.
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Figure 3. The complex tumour microenvironment of HGSOC
Immunohistochemical staining of high-grade serous ovarian cancer showing diversity and 
architectural features of immune cell infiltration. a | CD8+ cytotoxic T cell, CD4+ T helper 
cell and CD20+ B cell infiltration among tumour cells. b | Tertiary lymphoid structure 
resembling a lymph node, embedded in tumour, with defined T cell and B cell zones and 
associated high endothelial venules (HEVs). Tumour-infiltrating lymphocytes (TILs) are 
found in the adjacent tumour. c | CD8+ T cells are often surrounded by immunosuppressive 
elements such as programmed cell death protein 1 ligand 1 (PDL1)-expressing macrophages 
and tumour cells. d–f | Range of CD4+ and CD8+ T cell responses in different patient 
samples in terms of density and association with B cell infiltrate. High TIL density (part f) is 
most likely to be associated with therapeutic response to immune checkpoint inhibition. 
Images are courtesy of K. Milne, D. Kroeger and B.H.N..
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